Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA DSHEA "article" interpretation in Cholestin case "contrary" to statute -- Pharmanex.

This article was originally published in The Tan Sheet

Executive Summary

DSHEA "ARTICLE" INTERPRETATION BY FDA IN CHOLESTIN DECISION is "contrary to the statutory text" of the Dietary Supplement Health & Education Act, which incorporates an "established and authoritative prior interpretation" and "would produce absurd results," Pharmanex argues in a June 1 memorandum filed in Salt Lake City federal court. The company maintains the DSHEA provision excluding from dietary supplement status "an article that is approved as a new drug" does "not apply" to Cholestin, which is marketed as a dietary supplement for healthy cholesterol.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088507

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel